Clinical Trial Update: A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 pharmacodynamics study of RO5083945 in patients with head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• RO5083945

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Head and Neck Cancer | Phase 1 | Status: COMPLETED